Telix Pharmaceuticals ($TLX) Stock Hub 2026: The September 11 Pixclara Decision, The Unclosed Zircaix CRL And A US$1 Billion Revenue Year

01Executive Summary

Telix Pharmaceuticals is unusual among the companies covered in this series because the commercial argument is already settled. The company sold US$803.8 million of product in 2025, up 56% year on year, and it has followed that with US$230 million in the first quarter of 2026 and US$247 million in the second. Revenue is not the question. What is still open is whether the regulatory and manufacturing machine behind that revenue works as advertised.

The commercial base is prostate cancer imaging. Illuccix is approved and, according to the company, commercially available in 22 countries including the United States; Gozellix has FDA approval. Around that base Telix has been trying to add two more diagnostics and a therapeutics franchise, and this is where the record becomes uneven. Zircaix, the kidney imaging agent, received a Complete Response Letter on August 28, 2025 over chemistry, manufacturing and controls deficiencies, and the resubmission has not yet been publicly confirmed as accepted. Pixclara, the brain imaging agent, also received a Complete Response Letter, was resubmitted on March 13, 2026, accepted on April 10, 2026, and now carries a PDUFA goal date of September 11, 2026.

The balance sheet is the part that deserves the most attention and the least coverage. Telix ended 2025 with US$141.9 million of cash against a business guided to spend US$230 to US$270 million on research and development in 2026 alone, a figure raised from US$200-240 million at the July update. Adjusted EBITDA fell to US$39.5 million in 2025 from US$66.9 million in 2024, and the company reported a loss before tax of US$5.3 million. A company growing revenue at 56% while EBITDA falls is spending the growth, which is a defensible choice but not a free one.

There is also a legal overhang that is easy to miss in the product headlines. A securities class action, Thomas v. Telix Pharmaceuticals Ltd., was filed in the U.S. District Court for the Southern District of Indiana covering a class period from February 21, 2025 to August 28, 2025, and the company disclosed an SEC subpoena on July 22, 2025 relating to its prostate cancer therapeutics disclosures.

Two dates frame the picture. Half-year results for the period ended June 30, 2026 were reported on August 20, 2026, and the Pixclara decision is due on September 11, 2026.

02What The Company Actually Is Today

Telix is a commercial-stage radiopharmaceutical company founded in 2015, headquartered in Melbourne, listed on the Australian Securities Exchange and, since November 2024, on Nasdaq through an American Depositary Share programme. Stock Analysis lists 1,184 employees.

The company reports across three business areas, and reading them separately is the only way to make sense of the revenue line.

That table contains the whole investment argument in miniature. Precision Medicine is growing at 30% and carries the company. Manufacturing Solutions is shrinking modestly year on year. Therapeutics generates nothing and absorbs the majority of a research budget guided at up to US$270 million.

03Illuccix And Gozellix: The Commercial Base

Illuccix is a kit for the preparation of gallium-68 gozetotide injection, used for PSMA-PET imaging in prostate cancer. It is the product that made Telix a commercial company, and the company states it is commercially available in 22 countries including the United States. Gozellix has also received FDA approval.

The most concrete recent datapoint on this franchise is geographic rather than American. In the December 2025 portfolio update Telix reported that the Phase 3 study of Illuccix in China met its primary endpoint, with an overall patient-level positive predictive value of 94.8% (95% CI: 85.9%, 98.2%) across 140 patients, and that 67.2% of patients had their treatment plan changed as a result of the PSMA-PET imaging.

That second number is the commercially relevant one. A diagnostic that changes management in two thirds of cases is a diagnostic that clinicians order again. The China result does not by itself create revenue, because approval and reimbursement in that market are separate processes with their own timelines, but it supports the durability of the franchise that funds everything else.

04Pixclara: The September 11 Decision

TLX101-Px, brand name Pixclara, is an F-18 fluoroethyl-tyrosine PET agent for imaging recurrent or progressive glioma, intended to distinguish true tumour progression from treatment-related change in adult and paediatric patients. The clinical problem is real: after radiation and chemotherapy, standard MRI often cannot separate a growing tumour from treatment effect, and the two require opposite decisions.

The regulatory history is not clean, and reading it in order matters.

The application carries Orphan Drug and Fast Track designations, and Telix has pointed out that 18F-FET is already broadly recommended in international clinical practice guidelines, including NCCN guidelines. That is a genuine argument: the agent is used in Europe, and the unmet need is documented. It is also an argument the FDA has already heard once, since this is a resubmission after a Complete Response Letter.

A European marketing authorisation application has also been submitted, which spreads the regulatory risk across two agencies rather than concentrating it in one.

05Zircaix: The CRL That Is Not Yet Closed

TLX250-CDx, brand name Zircaix, is a zirconium-89 labelled girentuximab antibody for imaging clear cell renal cell carcinoma. The BLA was accepted with priority review in February 2025, which at the time was read as a near-term approval.

On August 28, 2025 the FDA issued a Complete Response Letter citing manufacturing deficiencies. The stock fell more than 21% on the disclosure. The FDA also documented deficiency notices at two third-party manufacturing partners requiring remediation before any resubmission.

In the December 22, 2025 portfolio update Telix reported a positive Type A meeting with the FDA to align on remediation of the CMC deficiencies, with a further meeting scheduled to discuss comparability data between the product used in the ZIRCON study and the commercial manufacturing process. In the April 2026 quarterly update the company described the BLA as being prepared for resubmission in the first half of 2026 and said alignment had been reached with the FDA on the critical issues.

As of August 28, 2026, no public announcement confirms that the Zircaix BLA has been resubmitted and accepted. That is a gap in the record rather than a negative datapoint, but it is a gap on the asset that caused the single largest one-day decline in the stock over the past year.

What the August 20 report added. Telix disclosed that it received a corrected Complete Response Letter, dated April 10, 2026, and that it has been granted an extension of the deadline for resubmitting the BLA. The company says it continues to work with the FDA so that the resubmission package addresses all outstanding items. Two things follow. A corrected letter means the original one contained something the agency itself needed to restate, which is unusual and is a fact rather than an interpretation. An extension of the resubmission deadline removes the immediate risk of a lapsed filing, and it also removes the date by which the market could have expected the file to move. In the same announcement the agent is named TLX250-Px, girentuximab senvedoxam, rather than the TLX250-CDx designation used earlier.

06The Therapeutics Pipeline

The therapeutics business is where the research budget goes and where no revenue yet comes from. Four programmes were referenced in the 2026 quarterly updates.

Read plainly, the therapeutics portfolio in mid-2026 is a set of studies that have just started dosing or just started enrolling. None of them produces a registrational readout in 2026. The R&D guidance increase to US$230-270 million is the cost of running them.

This is also the part of the business named in the securities litigation. The complaint alleges that management overstated the developmental progress and commercial prospects of TLX591 and TLX592 specifically. Whatever the eventual outcome of that case, it means the therapeutics disclosures are the ones that will be read most sceptically.

07Manufacturing Solutions And The Vertical Integration Bet

Telix Manufacturing Solutions generated US$45 million in the second quarter of 2026, down 6% year on year and up 2% sequentially. In FY 2025 the segment produced US$238.4 million, of which US$170.1 million came from third parties.

The strategic logic is straightforward. Radiopharmaceuticals decay; they cannot be stockpiled and shipped the way a tablet can. Owning radiopharmacy and distribution capacity is what makes a same-day imaging agent commercially viable at scale, and it also creates a third-party revenue stream from other companies that need the same infrastructure.

The counter-argument is what the last eighteen months demonstrated. The Zircaix Complete Response Letter was a manufacturing letter, and the deficiency notices extended to third-party partners. Vertical integration in this industry concentrates regulatory risk as much as it captures margin. A segment that is shrinking modestly year on year while carrying that risk is not yet paying for itself twice over.

08Revenue Trajectory And Guidance

The guidance was revised upward at the July 21, 2026 update. Group revenue guidance for FY 2026 is US$950 to US$970 million, and the company describes revenue and other income together as expected to exceed US$1 billion once a US$40 million non-refundable payment from Regeneron is included.

Two observations follow. First, the distinction between revenue and other income is not cosmetic: a one-off non-refundable partner payment is not a product sale, and the company itself presents them separately. Second, half-year revenue of roughly US$477 million against full-year guidance of US$950-970 million implies the second half needs to look very much like the first, with no acceleration required and none assumed.

09Financials

Telix reported its half-year results on August 20, 2026, and lodged them with the SEC on a Form 6-K the same day. That report replaces the FY 2025 accounts as the most recent complete income statement, and it answers three questions that were open until then: the first-half revenue on an audited basis, the June 30 cash balance, and what the Regeneron payment did to profitability.

How much of the profit is the business, and how much is Regeneron. Profit after tax of US$38 million includes US$40 million of other income from the Regeneron collaboration, a payment that does not repeat. Strip it out and the half is close to break-even at the bottom line, which is a different statement from the headline. The part that does not depend on it is the gross profit: US$260 million against US$209 million, on a group gross margin of 55%, which the company reports as up 2% year on year, with Precision Medicine at 65%. That is the engine.

Where the spending went. Research and development rose from US$82 million to US$124 million, up 51%, of which US$68 million went to the therapeutics pipeline. Selling and marketing rose 18% and manufacturing and distribution 53%, the latter reflecting the build-out of the manufacturing segment. General and administration was essentially flat. Spending is growing faster than revenue by design, and the company has reaffirmed full-year R&D guidance of US$230 to 270 million.

Segments. Precision Medicine revenue grew 27% year on year with segment adjusted EBITDA of US$132 million, up 26%. Manufacturing Solutions reported US$146 million of total segment revenue, of which US$89 million from third-party sales and service fees and US$58 million internal, with an operating loss of US$33 million and an adjusted EBITDA loss of US$23 million against a US$13 million loss a year earlier. The manufacturing arm is being funded, not harvested.

The FY 2025 comparison below is kept because it is the last full-year picture and it frames the trajectory.

Three things follow from that table. First, this is a company with real gross margin: 64% on more than US$800 million of revenue is a genuine commercial engine, not a licensing artefact. Second, adjusted EBITDA fell by 41% in a year when revenue grew 56%, because research spending rose faster than gross profit. Third, the loss before tax is small in absolute terms but includes US$26.7 million of non-cash finance costs tied to the convertible bonds, which is a reminder that the capital structure is not equity-only.

The 2026 guidance makes the direction explicit. R&D of US$230-270 million against FY 2025 R&D of US$157.1 million is a planned increase of between 46% and 72%. Revenue guidance of US$950-970 million against US$803.8 million is planned growth of 18% to 21%. Spending is guided to grow roughly three times faster than revenue.

10Balance Sheet And Capital Structure

The June 30, 2026 balance sheet is now public. Cash and equivalents stood at US$252 million, against US$141.9 million at December 31, 2025, and the company generated US$23 million of net cash from operating activities in the half. The increase is not operating cash alone: it also reflects the US$40 million Regeneron payment and the April refinancing, in which Telix issued US$600 million of new convertible bonds due 2031 to replace the existing convertible structure. Finance costs of US$19 million in the half are predominantly tied to that refinancing.

Set the cash position against guided 2026 research spending of US$230 to 270 million and the arithmetic is simple: a year of guided R&D is larger than the cash balance, and the intended funding source is the operating business, which produced US$260 million of gross profit in six months. The convertible bonds sit above that as a claim which converts into shares rather than being repaid in cash, if the conversion conditions are met.

A new at-the-market facility, announced the same day

In the same August 20 announcement, Telix disclosed that it had entered into an equity distribution agreement with Morgan Stanley & Co. LLC and William Blair & Company, L.L.C. to establish an at-the-market facility. Under it the company may issue new fully paid ordinary shares at prevailing market prices, in the form of American Depositary Shares on Nasdaq.

What it is and what it is not. Establishing an ATM is not an issue of shares. The company states that no offers or sales will be made unless and until a prospectus supplement is filed with the SEC, that it retains sole discretion over whether and when the facility is used, over the number of ADSs sold and over the minimum price, and that use remains subject to the ASX Listing Rules including available placement capacity. As of August 28, 2026 no prospectus supplement had been identified on EDGAR, so nothing has been issued under it.

Why it belongs in the risk section anyway. A company that has just reported a profitable half and a larger cash balance does not need an ATM to survive; it puts one in place to have the option of funding growth quickly and without a marketed transaction. That option has a cost for existing holders, because it is dilution that can arrive in small increments, at market prices, without the announcement that a placement would require. The line to watch is the share count in each subsequent report, and any prospectus supplement filed with the SEC.

11Listing Structure, ADS And Reporting Status

Telix is primarily listed on the Australian Securities Exchange under TLX. American Depositary Shares began trading on Nasdaq under the same ticker on November 14, 2024, with JPMorgan Chase Bank, N.A. as depositary. Each ADS represents one fully paid ordinary share, which is unusual and convenient: the Nasdaq price and the ASX price are directly comparable once currency is accounted for, with no ratio adjustment.

The company registered on Nasdaq via a Form 20-F registration statement and files with the SEC under CIK 0002007191. The practical consequence for a reader used to American small caps is that there is no 10-Q. Telix reports on the Australian cycle: half-year and full-year results, with quarterly business updates in between that carry revenue and pipeline but not a full balance sheet.

That reporting asymmetry explains why the cash position is six months stale in the public record while revenue is only weeks old. It is a disclosure regime difference, not an omission.

Liquidity is also split. Average Nasdaq ADS volume is thin relative to the market capitalisation, with 212,702 ADS traded on August 7, 2026 against a market capitalisation near US$3.9 billion. The primary liquidity pool remains the ASX line. A US-based reader trading the ADS is trading a secondary venue.

12Litigation And The SEC Subpoena

This section exists because the product headlines do not contain it and the risk section of any honest hub has to.

On July 22, 2025 Telix disclosed that it had received an SEC subpoena relating to disclosures concerning its prostate cancer therapeutics. The stock fell more than 13% on the disclosure. On August 28, 2025 the FDA issued the Zircaix Complete Response Letter citing manufacturing deficiencies, and the stock fell more than 21%.

A securities class action followed. Thomas v. Telix Pharmaceuticals Ltd. was filed in the U.S. District Court for the Southern District of Indiana, covering purchasers over a class period from February 21, 2025 to August 28, 2025, with a lead plaintiff deadline of January 9, 2026. The complaint alleges that management materially overstated the developmental progress and commercial prospects of TLX591 and TLX592, and misrepresented the stability, quality and regulatory compliance of the third-party supply chain and manufacturing partners.

Allegations in a complaint are allegations. What is not in dispute is the sequence: a subpoena, then a manufacturing-based Complete Response Letter, then deficiency notices at two third-party partners. That sequence is the reason the Zircaix resubmission carries more informational weight than its revenue potential would suggest.

13Analysts And Market Data

Market data below is as of the close on August 7, 2026 unless stated otherwise.

Analyst coverage

Coverage of the Nasdaq line is thin and unusually clustered. The consensus reported by Stock Analysis, drawing on S&P Global Market Intelligence and last updated August 10, 2026, is:

Two features of that table deserve attention rather than celebration. The first is unanimity: five out of five at the highest rating, with no dissent, is a narrow consensus rather than a robust one. The second is dispersion, or the lack of it: a range of $19.55 to $22.20 is a spread of about 14%, which is extraordinarily tight for a company with an open FDA question, an unresolved CRL and pending securities litigation. Tight consensus on a binary calendar usually means the binary is not being modelled.

14Retail Sentiment

The Nasdaq ADS line attracts limited retail attention, and this is a case where the honest reading is the absence of data rather than a number.

As of August 9, 2026 the Stocktwits $TLX stream showed 163 watchers and no sentiment series was returned, meaning there were too few sentiment-tagged messages to produce a bullish or bearish percentage. For comparison, actively discussed small caps covered elsewhere on this site carry watcher counts in the tens of thousands.

That is itself informative. A company with a US$3.9 billion market capitalisation, approved products and an FDA decision four weeks away has almost no American retail conversation around it. The shareholder base sits on the ASX and in institutional hands, and the ADS is a professional instrument rather than a retail one. It also means the September 11 decision is unlikely to be front-run by retail flow the way a comparable US-domiciled biotech PDUFA would be.

15What Bulls See

Revenue that is already there. US$803.8 million in FY 2025 and roughly US$477 million in the first half of 2026 is not a projection. Very few companies in the radiopharmaceutical sector have a commercial base of this size.

A 64% gross margin. Stable year on year on a growing revenue base, which means the growth is not being bought with discounting.

A near-term regulatory catalyst with a real clinical rationale. 18F-FET imaging is already recommended in international practice guidelines including NCCN, and the Pixclara indication addresses a documented diagnostic gap after glioma treatment.

Two shots at the same problem. A European marketing authorisation application for Pixclara is in parallel with the US filing, so a US setback does not close the asset.

Geographic runway on the core product. The China Phase 3 for Illuccix met its primary endpoint with 94.8% positive predictive value and changed management in 67.2% of patients, which extends the franchise that funds the pipeline.

Vertical integration that competitors have to build. Manufacturing Solutions generated US$170.1 million of third-party revenue in FY 2025, which is infrastructure other radiopharma companies are paying to use.

16What Bears See

Two Complete Response Letters on two separate assets. Pixclara and Zircaix both received CRLs. Pixclara has been resubmitted and accepted; Zircaix has not been publicly confirmed as resubmitted and accepted. That is a pattern, not an incident.

The CRLs were about manufacturing, not efficacy. Manufacturing and third-party supply chain compliance problems are structural and slower to fix than a data problem, and the FDA documented deficiencies at two external partners.

An SEC subpoena and a securities class action. Both concern the therapeutics disclosures, which are also the disclosures that justify the increased research budget.

EBITDA is going the wrong way. Adjusted EBITDA fell from US$66.9 million to US$39.5 million while revenue grew 56%, and 2026 guidance implies research spending grows roughly three times faster than revenue.

Spending is guided to outrun the cash balance. Cash of US$252 million at June 30, 2026 sits against guided 2026 R&D of US$230-270 million, so a full year of research costs more than the balance on hand and has to be funded by the operating business.

Convertible bonds in the capital structure. US$26.7 million of non-cash finance costs in FY 2025, with the outstanding principal and fully diluted count not restated in the public updates.

Analyst consensus is unanimous and tight. Five Strong Buys with a 14% spread between the high and low target, ahead of a binary FDA date, is a consensus that has room to move in one direction more than the other.

17Scenario Framework

The scenarios below organise what the next two dates can change. They are descriptions of possible paths, not forecasts and not recommendations.

Between those poles sits the most likely text: a half-year report that has confirmed the revenue already disclosed and answered the cash question, followed by a single-agent FDA decision that resolves one of the two open regulatory files and leaves the other exactly where it is.

18Bottom Line

Telix is one of the few radiopharmaceutical companies whose commercial model is already proven at scale. That is the part of the story that is settled, and it is settled by numbers that come from audited results rather than projections.

What is verified: US$477 million of first-half 2026 revenue at a 55% group gross margin, up 22% year on year; adjusted EBITDA of US$52 million including the US$40 million Regeneron payment; profit after tax of US$38 million; cash of US$252 million at June 30, 2026; an at-the-market facility established on August 20, 2026 and not yet drawn; FY 2026 guidance of US$950-970 million of revenue, with revenue and other income together guided above US$1 billion; a Pixclara PDUFA goal date of September 11, 2026; a Zircaix Complete Response Letter dated August 28, 2025 over manufacturing; an SEC subpoena disclosed July 22, 2025; and a securities class action in the Southern District of Indiana.

What is not yet verified: the conversion price and fully diluted effect of the 2031 convertible bonds, whether the Zircaix BLA has been resubmitted and accepted, and how much of the FY 2026 revenue guidance depends on the second half rather than the first.

The half-year report settled part of that on August 20, 2026: revenue of US$477 million, a group gross margin of 55%, cash of US$252 million and a new at-the-market facility. What it did not settle is regulatory, and that falls on September 11, 2026, the Pixclara decision. Everything else here is context for reading those two documents.